GT Biopharma showcased new preclinical data in an oral presentation at SITC demonstrating an enhanced effect of combining GTB-5550, a B7-H3-targeted tri-specific NK cell engager (TriKE®), with a KRAS inhibitor (KRASi), which was shown to sensitize pancreatic tumor cells to NK cell cytotoxicity The new data show that the combination promotes NK cell infiltration to provide superior disease control in orthotopic xenograft models, and provides novel mechanistic insight into KRAS-dependent anti-tumor NK regulat ...